← Leaderboards
Alexandra Sarah Annukka Piotrowski-Daspit
Yale University
$1,233,592
Attributed
$1,233,592
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $358.2K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,233,592 · 3
By mechanism
R00$856,198 · 1
K99$254,610 · 1
F32$122,784 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Peter M Glazer$37,467,142
- Joanne B Weidhaas$4,203,501
- Jordan S Pober$30,894,969
- Mark C Horowitz$12,566,953
- Micha Sam Raredon$103,744
Others in their field
Other Emerging Leaders on “Three Dimensional Cell Culture”
- Kambez Hajipouran Benam · Pneumax, Llc$5,395,568
- Andrew Josef Ewald · Johns Hopkins University$5,185,169
- Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor$4,128,550
- Esak Lee · Cornell University$4,026,359
- Ozgur Sahin · Medical University Of South Carolina$3,809,359
- Rebecca R Pompano · University Of Virginia$3,512,162
Research focus
Three Dimensional Cell CulturePublic HealthOther GeneticsScreening ProcedureTranslationsBiocompatible MaterialsInterdisciplinary StudyMutationPolymersScreeningClinically RelevantGenesCystic FibrosisEstersAminesGenetic DiseasesBiomedical EngineeringIn VivoPhysiologicalBurden Of IllnessDrug Delivery SystemsClinical TranslationBiodegradable Polymer3-Dimensional
Grant awards (9)
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis$248,999
R00 · FY2025 · HL · contact PI
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis- Supplement$109,200
R00 · FY2025 · HL · contact PI
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis$248,999
R00 · FY2024 · HL · contact PI
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis$249,000
R00 · FY2023 · HL · contact PI
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis$109,847
K99 · FY2022 · HL · contact PI
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis$34,916
K99 · FY2022 · HL · contact PI
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis$109,847
K99 · FY2021 · HL · contact PI
Developing Poly(amine-co-ester) Polymeric Delivery Vehicles and 3D Culture Screening Platforms for the Treatment of Hereditary Beta-thalassemia with Peptide Nucleic Acid Genome Editing Technology$63,746
F32 · FY2019 · HL · contact PI
Developing Poly(amine-co-ester) Polymeric Delivery Vehicles and 3D Culture Screening Platforms for the Treatment of Hereditary Beta-thalassemia with Peptide Nucleic Acid Genome Editing Technology$59,038
F32 · FY2018 · HL · contact PI